Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial

Artikel i vetenskaplig tidskrift
Författare J. de Boniface
J. Frisell
Y. Andersson
L. Bergkvist
J. Ahlgren
L. Ryden
Roger Olofsson Bagge
M. Sund
H. Johansson
D. Lundstedt
Publicerad i BMC Cancer
Volym 17
ISSN 1471-2407
Publiceringsår 2017
Publicerad vid Institutionen för kliniska vetenskaper, sektionen för kirurgi och kirurgisk gastroforskning, Avdelningen för kirurgi
Språk English
Länkar dx.doi.org/10.1186/s12885-017-3361-...
https://gup-server.ub.gu.se/v1/asse...
Ämnesord Breast cancer, Sentinel lymph node biopsy, Axillary lymph node dissection, Survival, Macrometastasis, AMERICAN-COLLEGE, EUROPEAN-ORGANIZATION, CLINICAL-PRACTICE, BIOPSY, Z0011, ONCOLOGY, SURGEONS, WOMEN, METASTASIS, MICROMETASTASES
Ämneskategorier Kirurgi, Cancer och onkologi

Sammanfattning

Background: The role of axillary lymph node dissection (ALND) has increasingly been called into question among patients with positive sentinel lymph nodes. Two recent trials have failed to show a survival difference in sentinel node-positive breast cancer patients who were randomized either to undergo completion ALND or not. Neither of the trials, however, included breast cancer patients undergoing mastectomy or those with tumors larger than 5 cm, and power was debatable to show a small survival difference. Methods: The prospective randomized SENOMAC trial includes clinically node-negative breast cancer patients with up to two macrometastases in their sentinel lymph node biopsy. Patients with T1-T3 tumors are eligible as well as patients prior to systemic neoadjuvant therapy. Both breast-conserving surgery and mastectomy, with or without breast reconstruction, are eligible interventions. Patients are randomized 1: 1 to either undergo completion ALND or not by a web-based randomization tool. This trial is designed as a non-inferiority study with breast cancer-specific survival at 5 years as the primary endpoint. Target accrual is 3500 patients to achieve 80% power in being able to detect a potential 2.5% deterioration of the breast cancer-specific 5-year survival rate. Follow-up is by annual clinical examination and mammography during 5 years, and additional controls after 10 and 15 years. Secondary endpoints such as arm morbidity and health-related quality of life are measured by questionnaires at 1, 3 and 5 years. Discussion: Several large subgroups of breast cancer patients, such as patients undergoing mastectomy or those with larger tumors, have not been included in key trials; however, the use of ALND is being questioned even in these groups without the support of high-quality evidence. Therefore, the SENOMAC Trial will investigate the need of completion ALND in case of limited spread to the sentinel lymph nodes not only in patients undergoing any breast surgery, but also in neoadjuvantly treated patients and patients with larger tumors.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?